Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He holds a BA from Cornell University and a PhD in Virology from Harvard University. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Not so long ago, his mother and father were not rich. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . Maryann received her Bachelor of Science in English from Northeastern University. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Rebecca conducts due diligence on biotechnology companies at RA Capital. She also has a Master's in Accounting from Boston College and is a CPA. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Adam Rosenberg is an Advisor for RA Capital Management. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. He earned his MS in Bioinformatics from Boston University. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . Nate Davis is an Analyst on the Investment Team at RA Capital Management. Drinking, Drugs & Smoking Not present. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Parents Need to Know. Chris Caliri is the Chief Information Officer at RA Capital Management. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Dan studied Network Communications & Information Services at Lincoln Technical. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Nadim Shohdy is an EIR at RA Capital. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. In this role, he will work to evaluate and incubate early-stage therapeutic programs. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder's 20% or so stake worth some $700 million. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. Lorena Chen is a Fund Controller at RA Capital Management. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Brendan is a Tax Director at RA Capital Management. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. Peter Kolchinsky is a founder and managing partner at RA Capital Management and author of "The Great American Drug Deal" (Evelexa Press, 2020). In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Phi previously worked as an Executive Assistant at Relay Therapeutics. Chris Morrison is an Editor at RA Capital Management. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. in Business Administration in Management Information Systems from Northeastern University. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Previously, Derek covered solid tumor oncology landscapes. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Mariagrace has a BS in Sociology from Suffolk University. Joe DeMaio is IT Operations Associate at RA Capital Management. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. Sarah teaches a course at Harvard Law School on venture capital fund formation. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. She previously worked as a Finance Associate at the MFA Companies. Copyright 2001-2023 RA Capital Management, L.P. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Milind attended the residential Executive Program at The Wharton School of Management. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Brackett has a BS in Biology with a minor in Spanish from Davidson College. Mariagrace previously worked as an Executive Assistant at MPM Capital. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Prior to RA Capital, he represented emerging companies and venture capital investment funds at two international law firms. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal.
Places For Rent $600 A Month Near Me, Exemple Sujet Grand Oral Bac 2021 Maths Svt, Urbandale School Board Meeting, British Senior Tennis Rankings, Burnley Express Public Notices, Articles P